Literature DB >> 8035374

Detecting and monitoring trophoblastic disease. New perspectives on measuring human chorionic gonadotropin levels.

L A Cole1, E I Kohorn, G S Kim.   

Abstract

The human chorionic gonadotropin (hCG) molecules in trophoblastic disease serum and urine samples are more heterogeneous, or degraded, than those in pregnancy samples. HCG immunoassays, particularly some of the new multiantibody sandwich tests, are designed primarily for pregnancy application and do not necessarily detect the degraded molecules found in trophoblastic disease samples. This leads to erroneous results and possibly false diagnoses. Care is needed in choosing the hCG test for monitoring trophoblastic disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8035374

Source DB:  PubMed          Journal:  J Reprod Med        ISSN: 0024-7758            Impact factor:   0.142


  4 in total

Review 1.  New discoveries on the biology and detection of human chorionic gonadotropin.

Authors:  Laurence A Cole
Journal:  Reprod Biol Endocrinol       Date:  2009-01-26       Impact factor: 5.211

2.  Can the FIGO 2000 scoring system for gestational trophoblastic neoplasia be simplified? A new retrospective analysis from a nationwide dataset.

Authors:  Y K Eysbouts; P B Ottevanger; L F A G Massuger; J IntHout; D Short; R Harvey; B Kaur; N J Sebire; N Sarwar; F C G J Sweep; M J Seckl
Journal:  Ann Oncol       Date:  2017-08-01       Impact factor: 32.976

3.  Current chemotherapeutic management of patients with gestational trophoblastic neoplasia.

Authors:  Taymaa May; Donald P Goldstein; Ross S Berkowitz
Journal:  Chemother Res Pract       Date:  2011-05-11

4.  Different hCG assays to measure ectopic hCG secretion in bladder carcinoma patients.

Authors:  J Mora; N Gascón; J M Tabernero; J Rodríguez-Espinosa; F González-Sastre
Journal:  Br J Cancer       Date:  1996-10       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.